Referenced Articles

This interdisciplinary list of articles highlights some of the diverse work that informs our research:

1. Woo SA, Cragg A, Wickham ME, et al. Preventable adverse drug events: Descriptive epidemiology. Br J Clin Pharmacol 2020;86(2):291-302.

2. Hohl CM, Woo SA, Cragg A, et al. Repeat adverse drug events associated with outpatient medications: a descriptive analysis of 3 observational studies in British Columbia, Canada. CMAJ Open 2019;7(3):E446-E53.

3. Zed PJ, Abu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008;178(12):1563-69.

4. Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001;38(6):666-71.

5. Patel H, Bell D, Molokhia M, et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. BMC Clin Pharmacol 2007;7(9):1-11.

6. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-05.

7. Canadian Institute for Health Information. Emergency Department Visits in 2014-2015. In: Hohl CM, ed., 2015.

8. Hohl CM, Badke K, Zhao A, et al. Prospective validation of clinical criteria to identify emergency department patients at high risk for adverse drug events. Acad Emerg Med 2018:epub.

9. Hohl CM, Partovi N, Ghement I, et al. Impact of early in-hospital medication review by clinical pharmacists on health services utilization. PLoS One 2017;12(2):e0170495.

10. Woo SA, Cragg A, Wickham ME, et al. Methods for evaluating adverse drug event preventability in emergency department patients. BMC Med Res Methodol 2018;18:160. [published Online First: Dec 4]

11. van der Linden CM, Jansen PA, van Marum RJ, et al. Recurrence of adverse drug reactions following inappropriate re-prescription: better documentation, availability of information and monitoring are needed. Drug Saf 2010;33(7):535-38.

12. Peddie D, Bailey C, Wickham M, et al. Challenges care providers face documenting adverse drug events: an observational study: BC Patient Safety & Quality Council, 2015.

13. Hohl CM, Small SS, Peddie D, et al. Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study. JMIR Public Health Surveill 2018;4(1):e21.

14. Zhang M, D’Arcy C, Holman J, et al. Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980-2003. BJCP 2007;63(2):164-70.

15. Nebeker J, Barach P, Samore M. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med 2004;140(10):795-801.

16. Accreditation Canada. Required Organizational Practices Handbook 2018. Ottawa, ON: Health Standards Organization 2018.

17. Borgsdorf LR, Miano JS, Knapp PR. Pharmacist-managed medication review in a managed care system. Am J Hosp Pharm 1994;51:772-7.

18. ISMP, HIROC. Medication Reconciliation and Medication Review: Complementary Processes for Medication Safety in Long-Term Care 2007 [updated Dec 30. Available from: accessed Feb 21 2020.

19. Government of Canada. Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law) Amendments to the Food and Drugs Act (Bill C-17) 2014 [Available from: accessed Oct 11 2019.

20. BCPSLS Central. Vanessa’s Law and mandatory reporting of serious adverse drug reactions and medical device incidents 2019 [updated Jul 25. Available from: accessed Feb 21 2020.

21. Peddie D, Small S, Wickham M, et al. Designing Novel Health ICTs to Support Work, Not Generate It: Five Principles. Stud Health Technol Inform 2017;234:262-68.

22. Canada Health Infoway. e-Prescribing: PrescribeIT 2020 [Available from: accessed Feb 21 2020.

23. Government of Canada. Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law): Questions/Answers 2014 [Available from: accessed Feb 27 2020.

24. Peddie D, Small SS, Badke K, et al. Designing an Adverse Drug Event Reporting System to Prevent Unintentional Reexposures to Harmful Drugs: Study Protocol for a Multiple Methods Design. JMIR Res Protoc 2016;5(3):e169.

25. Bailey C, Peddie D, Wickham M, et al. Adverse drug event reporting systems: a systematic review. Br J Clin Pharmacol 2016;82(1):17-29.

26. Canadian Institutes of Health Research. Knowledge Translation at CIHR 2015 [Available from: accessed Feb 21 2020.

27. Lomas J. Using ‘linkage and exchange’ to move research into policy at a Canadian foundation. Health Aff (Millwood) 2000;19(3):236-40.

28. Kitson A, Bisby M. Speeding up the spread: putting KT research into practice and developing an integrated KT collaborative research agenda. Edmonton: Alberta Heritage 2008.

29. Bartunek J, Trullen J, Bonet E, et al. Sharing and expanding academic and practitioner knowledge in health care. J Health Serv Res Policy 2003;8(Suppl 2):62-8.

30. Bowen S, Martens PJ. A model for collaborative evaluation of university-community partnerships. J Epidemiol Community Health 2006;60(10):902-7.

31. Lapaige V. “Integrated knowledge translation” for globally oriented public health practitioners and scientists: Framing together a sustainable transfrontier knowledge translation vision. J Multidiscip Healthc 2010;3:33-47.

32. Institute for Clinical Evaluative Sciences (ICES) Western. Data Impact Challenge II Answer Submission 2016 [Available from: accessed May 1 2018.